Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

CEO is asked to move to the U.S. to be closer to angel investors

It took less than a year for Armen Bakirtzian and his team at Intellijoint Surgical Inc. to take a first-of-its-kind medical technology and put it in the hands of doctors in about 10 hospitals in the United States. During this time, the Waterloo, Ont., company has grown to employ about 30 people. It recently released a second-generation version of its tool, which improves the accuracy of implant selection and positioning during hip replacement surgery.

Glenn Lowson/The Globe and Mail

1 of 5

When Intellijoint received FDA clearance for its second-generation device in September, 2015, it went from zero to 10 hospitals in the U.S. in just a few months, Mr. Bakirtzian says.

Glenn Lowson/The Globe and Mail

2 of 5

Since its launch six years ago, Intellijoint has raised money mostly from provincial and federal government programs, as well as Canadian angel investors and venture capital firms. But securing funding has become more difficult as the company advances to the next stage of growth, says Mr. Bakirtzian. “We’ve been chasing capital in Canada, but I’ve found the angels and venture-capital gap widening as we’ve shifted to the right of the commercialization spectrum,” he says. “It’s a significant challenge because we need capital to continue to develop and commercialize our product.”

3 of 5

Mr. Bakirtzian and his team are looking at funding sources beyond the country’s borders. There are a lot of U.S. and international investors interested in Intellijoint, he says, but they’re all pushing for the company to move to where the money is. “They request that the business assets be in their home country and that we hire in their home country,” says Mr. Bakirtzian. “But we want to keep our operations in Canada.

4 of 5

Story continues below advertisement

“We’re a Canadian company, our families are in Canada, and there’s a lot of engineering talent where we are in Waterloo. We’ve lived and breathed this question for the last two years,” he says. “We want to be in Canada, but should we move to the U.S. or another country to get the capital we need?”

Glenn Lowson/The Globe and Mail

5 of 5

Report an error Editorial code of conduct
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies